Results 111 to 120 of about 2,000 (177)

Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual, and other men who have sex with men in Spain. [PDF]

Lancet Reg Health Eur
Wikman-Jorgensen PE, Iniesta C, Ruiz-Algueró M, Estrada V, Pulido F, Perez-Molina JA, Llenas-García J.   +6 more
europepmc   +1 more source

Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis. [PDF]

Adv Ther
Hawkins N, Hazra A, Brizzi M, Thompson J, Grove R, Sieverding M, Budnik P, Scherzer J, Danchenko N, Anderson SJ, Dupont-Benjamin L.   +10 more
europepmc   +1 more source

Commentary on PURPOSE-1 and PURPOSE-2 trials of lenacapavir: a breakthrough in HIV prevention. [PDF]

Ann Med Surg (Lond)
Idrees M, Iftikhar H, Sohail F, Jadoon M, Khan MH.   +4 more
europepmc   +1 more source

Development of an NGS analysis pipeline for the analysis of HIV-1 sequencing data, and application of the pipeline for detecting resistance mutations to the novel capsid inhibitor lenacapavir

Lenacapavir is a highly-effective, first-in-class capsid inhibitor used for treatment and prophylaxis for Human Immunodeficiency Virus Type 1 (HIV-1) infection. Drug resistance mutations (DRMs) to lenacapavir, while rare, occur naturally in people living
Oh, Bryant Zhi Yang
core  

The Delivery Disconnect: Why We Could Not Model the Impact of Foreign Aid Reductions on Vertical HIV Transmission and What Remains Evident About Strategic Priorities. [PDF]

J Int AIDS Soc
Bilinski A, Ciaranello A, Ramaswamy A, Walters M, Webb K, Imai-Eaton JW.   +5 more
europepmc   +1 more source

Comparing carbon emissions from oral tenofovir disoproxil fumarate/emtricitabine for preexposure prophylaxis and long-acting injectables for HIV prevention. [PDF]

AIDS
Rodrigues K, Bahrambegi R, Reid M.
europepmc   +1 more source

Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks. [PDF]

J Acquir Immune Defic Syndr
VanderVeen LA, Selzer L, Chang S, Li J, Diamond TL, Asante-Appiah E, Llamoso C, Rhee MS, Callebaut C.   +8 more
europepmc   +1 more source

New therapy for HIV infections: Lenacapavir

reservedIl virus dell’immunodeficienza umana HIV è l’agente responsabile della sindrome da immunodeficienza acquisita (AIDS). Da quando è stata riconosciuta, negli anni ’80, ad oggi ha causato più di 40 milioni di decessi. L’infezione da HIV determina
BERDONDINI, LAURA
core  

Optimising scale-up of injectable lenacapavir for HIV pre-exposure prophylaxis in South Africa: A modelling study and economic evaluation. [PDF]

PLoS Med
Jamieson L, Johnson LF, Imai-Eaton JW, Subedar H, Bekker LG, Meyer-Rath G.   +5 more
europepmc   +1 more source

A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between Islatravir and Lenacapavir. [PDF]

J Clin Pharmacol
Zhang H, West S, Kwok N, Mkaya C, Ling J, Palaparthy R, Longo D, Gillespie G, Llamoso C, Rhee M, Marathe DD.   +10 more
europepmc   +1 more source